Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.